79128-70-4

Basic information

• Product Name: METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE
• Synonyms: METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE
• CAS NO: 79128-70-4
• Molecular Formula: C₁₃H₁₁NO₃S
• Molecular Weight: 261.3
• Mol File: 79128-70-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 99-101°
• Boiling Point: 333.6°C at 760 mmHg
• Flash Point: 155.6°C
• Appearance: /
• Density: 1.335g/cm³
• Vapor Pressure: 0.000135mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE(79128-70-4)
• EPA Substance Registry System: METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE(79128-70-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 79128-70-4(Hazardous Substances Data)

Usage

General Description

METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE, also known as 3-(benzoylamino)-2-thiophenecarboxylic acid methyl ester, is a chemical compound with the molecular formula C14H11NO3S. It is a derivative of thiophene, containing a benzoylamino group and a carboxylate ester. METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE is often used as a building block in organic synthesis and pharmaceutical research, where it can be utilized in the development of novel drugs and biologically active molecules. Its structural features make it a valuable intermediate in the production of various pharmaceuticals and agrochemicals, making it an important molecule in the field of medicinal and organic chemistry.

InChI:InChI=1/C13H11NO3S/c1-17-13(16)11-10(7-8-18-11)14-12(15)9-5-3-2-4-6-9/h2-8H,1H3,(H,14,15)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 618-32-6 Benzoyl bromide 
• 98-88-4 benzoyl chloride 

Downstream Products

• 158715-04-9 3-benzoylaminothiophene-2-carboxamide 
• 18678-14-3 2-phenyl-3H-thieno[3,2-d]pyrimidin-4-one 
• 79128-75-9 N-Thiophen-3-yl-benzamide 

Relevant articles and documents

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.